BMY's growth portfolio now accounts for more than half of revenues, with Reblozyl, Breyanzi and Cobenfy delivering strong gains. Those newer products are offsetting declines in legacy drugs, indicating an improving revenue mix and supporting the company’s growth profile.
BMY's growth portfolio now accounts for more than half of revenues, with Reblozyl, Breyanzi and Cobenfy delivering strong gains. Those newer products are offsetting declines in legacy drugs, indicating an improving revenue mix and supporting the company’s growth profile.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
